Articles

A rigorous look at semaglutide's proven benefits for weight loss, glycemic control, and cardiovascular outcomes — with honest gaps noted where the data runs thin.

A critical reading of the STEP 1 trial on semaglutide 2.4 mg dosage for weight loss — what the data shows, what it doesn't, and what comes next.

A research-oriented primer on GHK-Cu: what it is, what the literature supports, where the evidence is thin, and what to read next.

GHK-Cu has real human trial data behind it — more than most peptides. Here is what the evidence shows on skin, wound healing, and beyond.

A source-grounded review of GHK-Cu side effects, adverse events from trials, long-term unknowns, and how its safety profile compares to alternatives.

A deep-dive into GHK-Cu peptide: what human trials, animal studies, and cell-line work actually support, where the evidence is weak, and what researchers used for dosing.

A deep-dive into CJC-1295 versus sermorelin, tesamorelin, and ipamorelin — what clinical trials actually show, where the gaps are, and which peptide has the stronger case.

GHK-Cu vs BPC-157, Matrixyl, and EGF compared on efficacy, safety, and practical use. Read the evidence, get a verdict.

A deep-dive into BPC-157's real evidence base: what animal studies show, what human data exists, mechanisms, dosing protocols, and where the science falls short.

A research-grounded deep-dive into TB-500: what the preclinical evidence shows, how researchers have dosed it, known side effects, and where it stands vs. alternatives.

A source-grounded deep-dive into BPC-157 results across animal and human data, covering mechanisms, published dosing protocols, side effects, and what's still unknown.

What doses of BPC-157 have researchers actually used? A deep-dive into published protocols, mechanisms, safety signals, and the honest state of human evidence.

BPC-157 sits in a legal grey zone. Here is what the FDA, WADA, and international regulators have actually said — and what that means for research use.

A research-oriented primer on BPC-157: what it is, what the preclinical literature shows, how researchers dose it, and where the evidence actually ends.

A critical breakdown of BPC-157 side effect data, from preclinical findings to the near-total absence of controlled human safety trials.

Tirzepatide vs semaglutide and liraglutide: head-to-head efficacy, safety, cost, and dosing compared. A verdict-first guide for informed buyers.

TB-500 and BPC-157 compared on efficacy, safety, and practical use. See which peptide has stronger evidence for tissue repair and recovery decisions.

A deep-dive into tirzepatide's weight loss evidence, dual GIP/GLP-1 mechanism, published dosing protocols, side effects, and how it compares to semaglutide.

The claim that BPC-157 is orally bioavailable circulates widely in peptide forums. Here is what the actual literature supports and where the myth breaks down.

A source-anchored review of Selank research protocols for anxiety — doses, routes, durations, reported outcomes, and open questions from published studies.

GLP-1 agonists vs retatrutide for fat loss: head-to-head on efficacy, safety, and practical use. Evidence-based verdict for informed decision-making.

A research-focused primer on MOTS-c: its mitochondrial origin, metabolic mechanisms, preclinical findings, human trial data, and honest assessment of what is and isn't established.

A deep-dive into TB-500's evidence base for tendon recovery — covering preclinical data, proposed mechanisms, published dosing protocols, and where it stands vs. alternatives.